Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroprotective therapy.

J C Grotta1, S Hickenbottom

  • 1jgrotta@neuro.med.uth.tmc.edu

Revue Neurologique
|October 21, 1999
PubMed
Summary
This summary is machine-generated.

Neuroprotective therapy for stroke shows promise in animal models but fails in human trials. Future clinical trials must better mimic experimental conditions for successful neuroprotection development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis.

European journal of neurology·2020
Same author

Aspirin in stroke prevention.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Patient refusal of thrombolytic therapy for suspected acute ischemic stroke.

International journal of stroke : official journal of the International Stroke Society·2012
Same author

Safety of high doses of urokinase and reteplase for acute ischemic stroke.

AJNR. American journal of neuroradiology·2011
Same author

The effect of transcatheter injections on cell viability and cytokine release of mononuclear cells.

AJNR. American journal of neuroradiology·2010
Same author

Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia.

Neurology·2010
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Neuroprotective therapies aim to reduce brain damage following stroke.
  • Despite success in animal models, clinical translation of neuroprotective drugs for stroke has consistently failed.
  • Understanding the biochemical cascade post-stroke is crucial for therapeutic development.

Purpose of the Study:

  • To highlight the discrepancy between animal model efficacy and clinical trial outcomes for neuroprotective stroke therapies.
  • To propose that improved clinical trial design, mirroring experimental conditions, is essential for advancing neuroprotection.

Main Methods:

  • Review of existing neuroprotective drug trials for stroke.
  • Analysis of factors contributing to the success of neuroprotection in animal stroke models.

Related Experiment Videos

  • Comparison of experimental conditions in preclinical studies versus clinical trials.

    • Main Results:

    • Numerous neuroprotective agents effective in animal stroke models have not translated to clinical benefit.
    • Clinical trials have not adequately replicated the controlled environments where neuroprotective drugs demonstrated efficacy.
    • A gap exists in aligning preclinical efficacy with clinical trial design.

    Conclusions:

    • Current clinical trial designs for stroke neuroprotection are insufficient.
    • Future progress in neuroprotective therapy for stroke hinges on optimizing clinical trial methodologies.
    • Simulating preclinical success factors in clinical trials is paramount for effective neuroprotection.